Other OTC - Delayed Quote USD

Provectus Biopharmaceuticals, Inc. (PVCT)

0.1985 +0.0021 (+1.07%)
At close: April 26 at 3:50 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
2,909.7810
2,909.7810
3,391.4250
4,636.0190
4,931.6090
Operating Income
-2,909.7810
-2,909.7810
-3,391.4250
-4,636.0190
-4,931.6090
Net Non Operating Interest Income Expense
-216.2140
-216.2140
-163.6910
-961.6980
-1,744.7050
Other Income Expense
24.2270
24.2270
0.4330
58.1740
-1.2730
Pretax Income
-3,101.7680
-3,101.7680
-3,554.6830
-5,539.5430
-6,677.5870
Net Income Common Stockholders
-3,101.7680
-3,101.7680
-3,554.6830
-5,539.5430
-6,677.5870
Diluted NI Available to Com Stockholders
-3,101.7680
-3,101.7680
-3,554.6830
-5,539.5430
-6,677.5870
Basic EPS
-0.01
--
-0.01
-0.01
-0.02
Diluted EPS
-0.01
--
-0.01
-0.01
-0.02
Basic Average Shares
419,508.1460
--
419,470.3380
408,223.0040
393,252.3210
Diluted Average Shares
419,508.1460
--
419,470.3380
408,223.0040
393,252.3210
Total Operating Income as Reported
-2,901.2500
-2,901.2500
-3,427.9460
-4,672.2540
-4,963.5760
Rent Expense Supplemental
19.1340
19.1340
23.1960
31.0550
32.7550
Total Expenses
2,909.7810
2,909.7810
3,391.4250
4,636.0190
4,931.6090
Net Income from Continuing & Discontinued Operation
-3,101.7680
-3,101.7680
-3,554.6830
-5,539.5430
-6,677.5870
Normalized Income
-3,125.9950
-3,125.9950
-3,555.1160
-5,597.7170
-6,676.3140
Interest Income
--
--
--
0.0040
3.4150
Interest Expense
216.2140
216.2140
163.6910
961.6980
1,748.1200
Net Interest Income
-216.2140
-216.2140
-163.6910
-961.6980
-1,744.7050
EBIT
-2,885.5540
-2,885.5540
-3,390.9920
-4,577.8450
-4,929.4670
EBITDA
-2,876.6330
-2,876.6330
-3,380.0970
-4,564.9800
-4,687.6770
Reconciled Depreciation
8.9210
8.9210
10.8950
12.8650
241.7900
Net Income from Continuing Operation Net Minority Interest
-3,101.7680
-3,101.7680
-3,554.6830
-5,539.5430
-6,677.5870
Total Unusual Items Excluding Goodwill
24.2270
24.2270
0.4330
58.1740
-1.2730
Total Unusual Items
24.2270
24.2270
0.4330
58.1740
-1.2730
Normalized EBITDA
-2,900.8600
-2,900.8600
-3,380.5300
-4,623.1540
-4,686.4040
12/31/2020 - 1/15/1997

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CELUW Celularity Inc.
0.0255
0.00%
 
IPCIF Intellipharmaceutics International Inc.
0.0600
0.00%
 
ENZN Enzon Pharmaceuticals, Inc.
0.0835
-5.17%
 
MACK Merrimack Pharmaceuticals, Inc.
14.73
0.00%
 
IUGNF Imugene Limited
0.0510
-3.41%
 
NYMXF Nymox Pharmaceutical Corporation
0.3000
0.00%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
 
FLUO.ST FluoGuide A/S
48.90
+7.47%
 
RNXT RenovoRx, Inc.
1.2430
+0.24%
 
GTBP GT Biopharma, Inc.
3.3450
-8.86%